- Absence of permanent cure for migraine and growing genericization of drugs are growing the market.
- Over-reliance on over-the-counter painkillers and easy availability of generics are likely to restrain growth.
- Increasing healthcare expenditure, rise in prevalence of migraine and availability of specialty migraine drugs are driving the migraine market in the North America region.
Migraine is a debilitating pain disorder characterized by moderate to severe recurrent headaches. According to the report that has been published by Market Research Future (MRFR), the global migraine market size is anticipated to grow at a steady rate in the coming years.
Migraine is one of the common disorders that cause tender headaches and is generally associated with other indications such as nausea, vomiting and sensitivity to light, smell and sound. The occurrence of migraine is common in females rather than males. Hence global increase in population, especially female population has resulted in increased prevalence of migraine leading to the high demand for effective treatments in the global migraine industry.
The underlying mechanism of migraine is not fully known. However, increasing incidences of migraine that is triggered due to other causative disorders are fueling the growth of the global migraine market. Absence of permanent cure for migraine and growing genericization of drugs are creating multiple opportunities for pharmaceutical companies to introduce effective medication and treatment for the condition, leading to the growth of the global migraine market.
Changing lifestyles, increasing stress levels and rise in prevalence of hormonal imbalance leading to migraine are inducing high demand for proper medication in the global market, which in turn is driving the global migraine market towards higher verticals. On the flip side, over-reliance on over-the-counter painkillers and easy availability of generics are likely to act as restraints on the growth of the global migraine market.
The leading players profiled by MRFR in the report on the global migraine market are Allergan, Impax Laboratories, Abbott Laboratories, Inc., Eisai Inc., Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson, Klaria, Kowa Pharmaceuticals America, Luitpold Pharmaceuticals, Meda, Merck, OptiNose, AstraZeneca plc, and GlaxoSmithKline Plc.
The global migraine market research report has been segmented on the basis of types, treatment types and drug class. Based on types, the migraine market is segmented into episodic and chronic. Based on treatment types, the migraine market is segmented into abortive and preventive. Based on drug class, the migraine market is segmented into triptans, ergots and others.
In August 2018, University of Melbourne has launched a new course named ‘Mastering migraine management‘ which highlights the latest advances in migraine diagnosis and treatments for general practitioners. This course was built in one year by a team of neurologists and is made available on any smart device.
Geographically, the global migraine market is segmented into four major regions such as North America, Europe, Asia Pacific and the Middle East and Africa. Increasing healthcare expenditure, rise in prevalence of migraine and availability of specialty migraine drugs are driving the migraine market in the North America region. The growth of migraine market in the Asia Pacific region is fueled by increasing investments by key players in the emerging market in the developing economies of India and China. The migraine market in the Europe region is projecting high growth potential owing to the increasing demand for effective treatment for migraine in this region.